@partyroll59
Active 10 months, 2 weeks ago
Together, these findings suggest TP53 mutational status as a biomarker for response to USP7 inhibition. AG-221 clinical trial We find that Ewing sarcoma and malignant rhabdoid tumor (MRT), two pediatric cancers that are sensitive to other p53-dependent cytotoxic drugs, also display increased sensitivity to XL177A.The PB2 gene is one of the key […] View